TeSR™-AOF Data Overview
Hear directly from the creator of TeSR™-AOF, STEMCELL Scientist Kim Snyder, as she explains the rationale behind TeSR™-AOF and gives a detailed overview of some preliminary data in this talk from the Till & McCulloch Meetings 2020.
Publish Date:
January 18, 2021
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
Related Multimedia
-
Nature Research Round Table: Retinal Cell Therapy Using Human Embryonic Stem Cells
Publish Date: November 01, 2019 -
Nature Research Round Table: hPSC Lines for Cell Therapies - Panel Discussion
Publish Date: November 01, 2019 -
Quality Control Guidelines for Clinical-Grade Human Induced Pluripotent Stem Cell Lines
Publish Date: June 09, 2020
Explore Our Products
-
Defined, xeno-free matrix that supports the growth and differentiation of human pluripotent stem cells under serum-free, feeder-free conditions -
cGMP, animal origin-free, stabilized, feeder-free maintenance medium for human ES and iPS cells -
cGMP, enzyme-free human pluripotent stem cell selection and passaging reagent -
Dilution buffer for matrix proteins, e.g. Vitronectin XF™
